Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections
Drugs used to treat blindness-causing disorders could be successfully administered by eye drops rather than unpleasant and expensive eye injections, according to new research led by UCL scientists that could be a breakthrough for the millions worldwide suffering from age-related macular degeneration (AMD) and other eye disorders.
1 in 5 people over 75 have AMD with well-known sufferers including actress Dame Judi Dench and author Stephen King. The research findings are significant due to growing patient numbers and an increasing demand for the eye injections that halt the progression of the disease.
The research, demonstrated in animal models and published today in nanotechnology journal Small, demonstrates that it is possible to create formulations of tiny nanoparticles loaded with the AMD drug Avastin and deliver significant concentrations to the back of the eye.
Lead author Professor Francesca Cordeiro (UCL Institute of Ophthalmology) said: “The development of eye drops that can be safely and effectively used in patients would be a magic bullet – a huge breakthrough in the treatment of AMD and other debilitating eye disorders.
“The current treatment of injecting drugs into the eye is uncomfortable, detested by patients and often needs repeated monthly injections in hospital for as long as 24 consecutive months. It’s impossible to exaggerate the relief patients would feel at not having to experience injections into their eyes.”
The NHS is currently overburdened with patients who need repeat eye injections and the numbers are set to rise exponentially over the next ten years. Demand is so high that injections are difficult to administer, time-consuming and very expensive. The treatment also carries a risk of infection and bleeding, increased by the frequency of recurrent injections into the eyes.
In the USA, well over one million ocular injections were given in 2010. In the UK, 30,500 injections were estimated to have been given in 2008 – a 150-fold increase in 10 years.
Effective delivery of drugs to the retina of the eye is considered one of the most challenging areas in drug development in ophthalmology, due to the presence of anatomical barriers. It was previously thought that drugs used to treat AMD such as Avastin and Lucentis have molecules that are simply too large to be effectively transported in an eye drop.
First author Dr Ben Davis (UCL Institute of Ophthalmology) added: “There is significant interest in the development of minimally invasive systems to deliver large drug molecules across biological barriers including the cornea of the eye.
“We have shown in experimental models a formulation system to get substances including Avastin across the barriers in the eye and transport them across the cells of the cornea. In theory, you could customise the technology for different drugs such as Lucentis, commonly used for AMD treatment in the UK, as it is a smaller molecule than Avastin so likely to be delivered effectively via this method.
“All the components we used are safe and well established in the field, meaning we could potentially move quite quickly to get the technology into trials in patients – but the timescales are dependent on funding.”
The Latest on: Age-related macular degeneration
via Google News
The Latest on: Age-related macular degeneration
- Kodiak (KOD) Closes Enrollment in Phase IIb/III Wet AMD Studyon November 17, 2020 at 10:16 am
Kodiak Sciences Inc. KOD announced that it has completed enrollment in the pivotal phase IIb/III DAZZLE study, which is evaluating its lead pipeline candidate KSI-301 for the treatment of patients ...
- Global Home-based Ophthalmic Monitoring Solutions Market 2020: A Transformative Mega Trend in the Ophthalmology Practiceon November 17, 2020 at 12:12 am
Dublin, Nov. 17, 2020 (GLOBE NEWSWIRE) -- The "Home-based Ophthalmic Monitoring Solutions, 2020" report has been added to ResearchAndMarkets.com's offering. Eye diseases such as glaucoma, age-related ...
- Adverum ticks lower on underwhelming data from gene therapy in wet-AMDon November 16, 2020 at 4:50 pm
(ADVM -3.8%) has reported new interim data from Cohorts 1-4 of the OPTIC Phase 1 trial evaluating its ADVM-022 intravitreal injection gene therapy in patients requiring frequent anti-VEGF injections ...
- Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degenerationon November 16, 2020 at 3:54 am
We are pleased to have exceeded our enrollment target for DAZZLE and to have recruited the study in just over one year despite the challenges presented by the COVID-19 pandemic. We are very grateful ...
- Adverum Biotechnologies Announces Positive Interim Data from Cohorts 1-4 from OPTIC Phase 1 ...on November 14, 2020 at 7:02 am
VEGF protein expression observed at 18 months in Cohort 1 – -- Well tolerated with ocular cell grades and steroid eye drop use decreasing over time -- -- First p ivotal trial planned for mid-2021 ...
- Gyroscope initiates phase III HORIZON trial of GT005 to treat dry age-related macular degenerationon November 12, 2020 at 4:30 am
Gyroscope initiates phase III HORIZON trial of GT005 to treat dry age-related macular degeneration: London Thursday, November 12, 2020, 18:00 Hrs [IST] Gyroscope Therapeutics, a c ...
- Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degenerationon November 11, 2020 at 2:00 am
Gyroscope Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry AMD.
- Groundbreaking stem cell research could restore sight to people with macular diseaseson November 10, 2020 at 4:49 am
Eye research charity Fight for Sight has announced funding for a ground-breaking stem cell research study which could reverse sight loss for people with macular diseases such as age-related macular ...
- Age Related macular Degeneration Market 2020 : Global Industry Analysis by Top Countries Data with Size, Drivers and Growth Insights to 2023on November 10, 2020 at 2:08 am
Kenneth Research has recently added a market research study on Age Related macular Degeneration Market 2023 which ...
- Celebrity Vince Hill joins The Macular Society as patronon November 5, 2020 at 8:08 am
An Andover-based charity has welcomed a new celebrity patron who used to be one of its clients. Vince Hill, the singer and TV presenter best known for reaching number two in the charts with Edelweiss, ...
via Bing News